ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Pharmaxis Releases Positive Results of for LOXL2 Trial
americanpharmaceuticalreview
October 12, 2018Pharmaxis announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fib
Pharma Sources Insight July 2025
